MedCity News
NOVEMBER 20, 2023
Multiple studies have shown no correlation between R&D costs and the launch price of new drugs though that is an argument often used by drugmakers to prevent a cap on pricing. Still, one way to keep costs low, is for organizations to leverage health technology like AI and improve formulary compliance.
PharmaVoice
NOVEMBER 20, 2023
Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
NOVEMBER 20, 2023
AI may transform health care across the board, but not by itself. It’s a tool, and like any tool, it will work more effectively and more safely in trained hands. As the AI revolution continues to grow, we believe organizations should invest in that training now.
Fierce Pharma
NOVEMBER 20, 2023
After blasting the U.K.’s drug pricing policy, the pharma industry has secured a new government spending deal featuring a higher revenue cap and an innovative drug-friendly rebate mechanism. | After blasting the U.K.’s drug pricing policy, the pharma industry has secured an improved government spending deal. The agreement will double the annual growth rate for prescription meds over the coming years.
Advertiser: ZoomInfo
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
MedCity News
NOVEMBER 20, 2023
Many digital health startups aren’t built with Medicaid members in mind. That’s why Health Net created a request for information process to help the insurer determine which startups are the best fit for its Medicaid population, according to Dr. Pooja Mittal, vice president and chief health equity officer at Health Net.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 20, 2023
Engaging parents in their kids’ mental health treatment can improve health outcomes. With digital health, it’s easier to do this, according to one mental health executive.
Fierce Pharma
NOVEMBER 20, 2023
It appears Bristol Myers Squibb’s multiple myeloma cell therapy Abecma will not end the year on a happy note. | It appears Bristol Myers Squibb’s multiple myeloma cell therapy Abecma will not end the year on a happy note. The company’s effort to gain approval for the CAR-T in an earlier line of treatment—previously set for an FDA decision on Dec. 16—will have to be pushed back pending an advisory committee meeting.
MedCity News
NOVEMBER 20, 2023
Experts agree there are some concrete steps healthcare providers can take to ensure AI will be integrated more smoothly and equitably. Some of these measures include ensuring that models are trained on diverse datasets, keeping clinicians in the loop and prioritizing patient consent.
Fierce Pharma
NOVEMBER 20, 2023
The threat of microbial contamination has triggered yet another drug recall, this time from German pharma bigwig Bayer. | Bayer is recalling one lot of Vitrakvi oral solution in the U.S. after routine stability testing discovered the presence of microbial contamination identified as Penicillium brevicompactum.
Speaker: Jesse Hunter and Brynn Chadwick
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
MedCity News
NOVEMBER 20, 2023
GUIDE — Guiding an Improved Dementia Experience — is the new dementia care model from the CMS and the CMMI (Centers for Medicare and Medicaid Innovation) for beneficiaries covered by traditional fee-for-service (FFS) Medicare and their caregivers. It represents an incremental step forward in managing neurodegenerative diseases effectively.
Fierce Pharma
NOVEMBER 20, 2023
Thanks to a new FDA approval, patients with ultra-rare desmoid tumors now have an FDA-approved treatment. | Patients with ultra-rare desmoid tumors now have an FDA-approved treatment, thanks to a drug made by SpringWorks Therapeutics, which spun out of Pfizer in 2017 with a portfolio of rare disease candidates.
MedCity News
NOVEMBER 20, 2023
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.
Fierce Pharma
NOVEMBER 20, 2023
Teva’s latest play in its yearslong defense against kickback claims levied by the U.S. government has secured the company a slight legal reprieve. | With the high-stakes trial now on pause, the U.S. First Circuit Court of Appeals will review a prior ruling that determines how the case can play out.
Advertiser: ZoomInfo
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
MedCity News
NOVEMBER 20, 2023
An independent data monitoring committee concluded Bayer’s experimental drug for atrial fibrillation would not be more effective than Eliquis, a blockbuster product currently used for the indication. Consequently, Bayer decided to stop that Phase 3 test for the once-daily oral small molecule.
PharmaTimes
NOVEMBER 20, 2023
The OpenSAFELY platform will support the discovery of new treatments - News - PharmaTimes
pharmaphorum
NOVEMBER 20, 2023
Eversana taps Adobe Firefly in quest to ‘pharmatise’ genAI Phil.
PharmaTimes
NOVEMBER 20, 2023
The centre will help discover new treatments to prevent, halt and cure the condition - News - PharmaTimes
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
pharmaphorum
NOVEMBER 20, 2023
'Landmark' deal reached on UK voluntary rebate scheme Phil.
Pharmaceutical Technology
NOVEMBER 20, 2023
Takhzyro has been approved for the routine prevention of recurrent hereditary angioedema attacks in patients aged 2 years and older.
pharmaphorum
NOVEMBER 20, 2023
Bayer pulls atrial fibrillation study for asundexian Phil.
Eversana Intouch
NOVEMBER 20, 2023
In the rapidly changing landscape of global markets, staying ahead of the curve is crucial for businesses aiming to expand and thrive. As we step into 2024, the realm of market access undergoes dynamic shifts influenced by technological advancements, policy changes, and evolving consumer behaviors. There are the usual suspects like evolving provider models, the continued transition to value-based care and pharma/biotech companies increased investment in “access,” but there are two trends that ar
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
pharmaphorum
NOVEMBER 20, 2023
AZ launches digital clinical trials business Phil.
Pharmaceutical Technology
NOVEMBER 20, 2023
AstraZeneca has launched a new digital health solutions business, Evinova, to expedite innovation in the life sciences industry.
pharmaphorum
NOVEMBER 20, 2023
The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in Germany next year.
Pharmaceutical Technology
NOVEMBER 20, 2023
The value of haemophilia gene therapies like Roctavian and Hemgenix hinge on long-term efficacy and innovative payment structures play a key role.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
pharmaphorum
NOVEMBER 20, 2023
Generics group says VPAG may lead to shortages Phil.
Copyright Clearance Center
NOVEMBER 20, 2023
“A good coach can change a game,” said UCLA’s John Wooden. “A great coach can change a life.
European Pharmaceutical Review
NOVEMBER 20, 2023
Eli Lilly and Company has announced that it plans to construct a new $2.5 billion parenteral (injectable) manufacturing site in Alzey, Rhineland-Palatinate, Germany. Supporting European parenteral manufacture and supply Alongside expanding the company’s global parenteral product and device manufacturing network, the new facility will support the higher demand for Eli Lilly’s medicines, including its diabetes and obesity portfolio.
Expert insights. Personalized for you.
331 
Let's personalize your content